摘要
目的:观察山香圆颗粒联合抗病毒颗粒治疗小儿急性上呼吸道感染的临床疗效和安全性观察。方法:将812例急性上呼吸道感染患儿随机分组,其中治疗组406例,给予山香圆颗粒联合抗病毒颗粒治疗;对照组406例,给予抗病毒颗粒治疗;疗程均为3d。观察两组患儿临床治疗效果以及不良反应情况。并对比其流涕及鼻塞停止时间、退热时间、咽部充血消失时间以及咳嗽停止时间。结果:治疗组各项临床时间指标均短于对照组,差异具有统计学意义(P<0.05);两组患儿治疗过程中及治疗后均无不良反应发生;治疗组总有效率为91.6%,高于对照组的78.3%,差异显著(P<0.05)。结论:山香圆颗粒联合抗病毒颗粒治疗小儿急性上呼吸道感染安全性较高,临床疗效显著,无不良反应情况发生,值得临床推广应用。
Objective： To observe the clinical efficacy and safety of turpinia particles combined antiviral granules in treatment of children with acute upper respiratory tract infection. Methods： 812 cases of upper respiratory tract infection were randomly divided into treatment group and control group. 406 patients in treatment group were treated with turpinia particles combined antiviral granules,while 406 patients in control group were given antiviral granules,3 days for a course of treatment,both groups were cured for 3 days. To compared the disappeared time of fever,cough,stuffy nose,sore throat,pharyngeal hyperemia,adverse reactions,clinical efficacy. Result： The disappeared time of clinical symptoms of treatment group was significantly less than the control group（ P〈0. 05）; There were no adverse reactions in both of two groups. The cured rate in treatment group were significantly higher than the control group（ P〈0.05）. Conclusion： The turpinia particles combined antiviral granules has a good effect in treatment of children with acute upper respiratory tract infection,there＇s no adverse reactions in both of two groups,which is appropriate to use in clinical.
出处
《河北医学》
CAS
2015年第10期1605-1607,共3页
Hebei Medicine
基金
贵州省黔东南洲科技项目
[编号:黔东南科合J字(2014)4032号]
关键词
山香圆颗粒
抗病毒颗粒
小儿
急性上呼吸道感染
临床疗效
安全性
Turpinia particles
Antiviral granules
Children
Upper respiratory tract infection
Clinical curative effect
Security
